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The effects of recombinant tissue plasminogen activator 
(rt-PA) and urokinase on patency and early reocclusion of 
infarct-related coronary arteries were investigated in a 
single blind, randomized multicenter trial in 246 patients 
with acute myocardial infarction of <6 h duration. Both 70 
mg of single chain rt-PA with an initial bolus of 10 mg and 
3 million units of urokinase with an initial bolus of 1.5 
million units were given intravenously over 90 min. The 
first angiographic study at the end of the infusion revealed 
a patent infarct-related artery (Thrombolysis in Myocar-
dial Infarction trial [TIMI] grade 2 or 3) in 69.4% of 121 
patients given rt-PA versus 65.8% of 117 patients given 
urokinase (p = NS). Among patients treated within 3 h 
from symptom onset a patent infarct-related artery was 
found in 63.9% of 72 patients given rt-PA versus 70% of70 
patients given urokinase (p = NS). 
Recent studies (1,2) have reported recombinant tissue plas-
minogen activator (rt-PA) to be more effective in early 
recanalization of infarct-related coronary artery occlusion 
than streptokinase. The risk of bleeding, however, which 
had been thought to be reduced with the new fibrin-specific 
agent, was significantly less in one study (1) but similar to 
that of streptokinase in another (2) despite a lesser degree of 
fibrinogenolysis with rt-PA (1,2). Furthermore, the short 
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There were five cardiac deaths in each group and one 
fatal intracranial hemorrhage in the rt-PA group. The 
in-hospital reinfarction rate was 8.9% versus 13.2% for 
patients treated with rt-PA and urokinase, respectively. 
There was no difference in left ventricular function at 
baseline and follow-up catheterization studies. Both drugs 
were well tolerated and there was no significant difference 
in cardiovascular or bleeding complications between the 
two groups. 
It is concluded that rt-PA and urokinase in the dosages 
used provide similar efficacy and safety in the treatment of 
acute myocardial infarction. Reocclusion during the first 24 
h may be less frequent after urokinase treatment. 
(J Am Coil CardioI1988;12:581-7) 
half-life of rt-PA may lead to a high incidence of early 
reocclusions unless the infusion is prolonged to :::::3 h (3), 
which in turn increases the risk of bleeding (4). Because 
intravenous urokinase is both effective in early reperfusion 
(5) and possibly associated with a lesser incidence of reoc-
clusion than rt-PA as a result of a longer half-life and an 
extended systemic fibrinolysis, the effects of rt-PA and 
urokinase on patency and early reOCclusion of infarct-related 
arteries were compared in a randomized single-blind multi-
center trial (German Activator Urokinase Study [GAUS]). 
Methods 
Study patients. From March 1986 to February 1987,246 
patients aged 25 to 75 years with an acute myocardial 
infarction of > 30 min and <6 h duration were enrolled into 
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the study. Inclusion criteria consisted of typical symptoms 
of acute myocardial infarction and ST segment elevation in 
:::::2 of the 12 leads of the standard electrocardiogram (ECG), 
> 1 mm in standard leads and > 2 mm in precordial leads. 
Exclusion criteria were a known bleeding disorder, oral 
anticoagulation, peptic ulcer during the last 3 months, in-
flammatory bowel disease, esophageal varices, aortic aneu-
rysm, uncontrolled hypertension (systolic blood pressure 
:::::200 mm Hg or diastolic blood pressure :::::110 mm Hg), 
external cardiac massage, complicated puncture of deep 
veins, trauma or operation within the last 6 months, short-
term headache of unknown origin, cancer, bacterial endo-
caiditis, pregnancy or any other condition posing an in-
creased risk of bleeding during fibrinolysis as judged by the 
physician in charge. Patients who were unable to give 
informed consent were also excluded. 
After informed consent, written or witnessed, was ob-
tained, the patient's identification was transmitted by phone 
to the data center for randomization, and the code number of 
the prepackaged lytic substance to be given to that patient 
was obtained. The sample size of the study was computed to 
be 434 patients (0: = 5%, f3 = 10%) assuming a 70% patency 
rate of the infarct -related artery in the rt -P A group and 55% 
in the urokinase group at the 90 min-angiographic study. It 
was decided to have data analysis performed at predefined 
sample sizes of 100, 200 and 300 patients by an independent 
statistician to report to the ethics committee and stop the 
study before the preset sample size, in case a significant 
difference in patency rates or complications would be ob-
served or no significant difference could be extrapolated for 
the preset maximal sample size. Accordingly, the trial was 
stopped on January 31, 1987 on the basis of the last interim 
analysis of 190 patients, which at the 90 min coronary 
angiographic study revealed a 0.2% difference in perfusion 
(Thrombolysis in Myocardial Infarction trial [TIM I] grade 3) 
and a 6.2% difference in perfusion TIMI grade 2 between 
rt-PA and urokinase. 
Treatment protocol. Patients randomized to rt-PA treat-
ment (n = 124) received a bolus of 5,000 U heparin followed 
by a sequence of intravenous rt-PA infusions, 10 mg by bolus 
injection, 50 mg over 1 h and another 10 mg over 30 min 
(predominantly single-chain rt-PA, Genentech Inc., supplied 
by Thomae). Patients randomized to urokinase (n = 121) 
received a bolus of 5,000 V heparin followed by a bolus of 
1.5 million units of urokinase and another 1.5 million units 
over 90 min (Alphakinase, Alpha Therapeutic GmbH). Pre-
treatment angiogrllphic study was not performed. During 
infusion of the fibrinolytic drugs, the patients were trans-
ferred to the catheterization laboratory, and the first angio-
graphic study was started by opacification of the presumed 
infarct-related artery 90 min (range 90 to lOS) after the onset 
of fibrinolytic therapy, followed by the opacification of the 
remaining coronary arteries in at least two projections of the 
right and three projections of the left coronary artery. 
Angiographic study was followed by left ventriculography, 
either single plane in the 30° right anterior oblique projection 
or biplane in 30° right anterior oblique and 60° left anterior 
oblique projections. 
The investigators were free to perform further recanali-
zation procedures at the end of the 90 min angiographic 
study such as intracoronary or prolonged intravenous throm-
bolysis or coronary angioplasty, which had to be docu-
mented by cineangiographic study and in the protocol. When 
the Judkins technique was used, the investigators were 
asked to repeat the coronary angiographic studies of the 
infarct-related artery after 24 h (range 12 to 36) before 
removal of the introducer sheaths. A second complete 
coronary and ventricular angiographic study was performed 
10 to 28 days later or before hospital discharge when 
indicated. 
Twelve lead ECGs were recorded before treatment, after 
3, 24 and 48 h and before the last angiographic study or at 
hospital discharge. Creatine kinase-MB fraction (MB CK) 
serum levels were measured before treatment and at 4 h 
intervals up to 48 h; fibrinogen levels were measured before 
treatment and after 3 and 24 h. 
A detailed analysis of hemostatic and fibrinolytic varia-
bles was undertaken in a large subset of patients; it will be 
reported separately. 
Anticoagulation was instituted after fibrinolysis with in-
travenous heparin when the thrombin time had returned to 
2.5 times normal or the partial thromboplastin time to 1.5 
times normal values and was maintained during the hospital 
stay either by intravenous or subcutaneous heparin or by an 
oral anticoagulant agent. 
Reinfarction was defined as an anginal episode of >30 
min duration unresponsive to nitrates and associated with 
significant ST segment elevation, regardless of new Q waves 
and a significant increase of cardiac enzymes. 
Assessment of coronary and ventricular angiograms. 
Each angiogram was graded for patency and perfusion of the 
infarct-related artery by two experienced investigators 
(K.L.N. and V.T.) according to the classification criteria of 
the TIMI study group (2). The investigators were unaware of 
the treatment mode. The infarct-related artery was identified 
from the sequential angiograms and the ST segment changes 
in the ECG. Left ventricular ejection fraction was assessed 
from the 30° right anterior oblique single plane ventriculo-
gram with the use of the formula of Sandler and Dodge (7). 
All angiocardiograms were then sent to the central angio-
graphic study analysis at Erlangen for quantitative assess-
ment of the infarct-related artery (7) and regional and global 
ventricular function. 
In this report, only data of the central evaluation in 
Goettingen will be reported. A total of seven angiograms at 
90 min could not be analyzed (three from patients receiving 
rt-PA and four from patients receiving urokinase): three 
were missed for technical reasons and in two patients (one 
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Table 1. Selected Baseline Variables of 245 Patients on Admission 
rt-PA UK 
(n = 124) (n = 121) 
Men(%) 83.1 87.6 
Age (yr) 57 ± 10 57 ± 10 
Time from onset of symptoms 
to infusion (h) 
o to 2 27 (21.8%) 34 (28.1%) 
>2 to 4 74 (59.7%) 60 (49.6%) 
>4 t06 23 (18.5%) 27 (22.3%) 
Systolic blood pressure 134 ± 22 128 ± 23* 
(mmHg) (80 to 190) (60 to 180) 
Diastolic blood pressure 83 ± 11 80 ± 14 
(mmHg) (50 to 105) (20 to 105) 
Heart rate 77 ± 18 79 ± 21 
(beats/min) (43 to 130) (20 to 182) 
Pulmonary rales 15 (12.1%) 25 (20.7%) 
MB CK (V/liter) 8.7 ± 10.4 8.2 ± 8.4 
(n = 90) (n = 86) 
Anterior MI 65 (52.4%) 53 (43.8%)t 
Previous MI 18 (14.5%) 20 (16.5%) 
Diabetes mellitus 13 (10.5%) 16 (13.2%) 
*p = 0.04; tp = 0.08. MB CK = serum creatine kinase, MB fraction; MI 
= myocardial infarction; rt-PA = recombinant tissue plasminogen activator; 
VK = urokinase. 
rt-PA and one urokinase) the first angiographic study was 
not performed for clinical reasons; one patient refused 
angiographic study after randomization and one angiogram 
was lost in the mail. 
Statistical analysis. The proportion of events in the two 
treatment groups were compared by standard methods. 
Ordered variables were compared by the Mann-Whitney U 
test; where appropriate, chi-square and t tests were used. 
The chi-square test was corrected according to Yates, when 
the number of events was <5 in at least one group. 
Results 
Clinical features and events. Two-hundred forty-five pa-
tients received the study medication (rt-PA in 124 and 
urokinase in 121). One patient allocated to rt-PA did not 
receive the study medication because a contraindication 
(oral anticoagulant therapy) was detected before the start of 
infusion. With respect to baseline variables, there was no 
major difference between the two treatment groups (Table 
1). Systolic blood pressure was slightly higher and the 
proportion of anterior infarction was slightly larger in the 
rt-PA than in the urokinase group (52.4 versus 43.8%, p = 
0.08). Treatment groups did not differ with respect to med-
ical therapy before thrombolysis including pretreatment with 
intravenous nitroglycerin. 
Two major incidents occurred between the onset of 
Table 2. Patency of Infarct-Related Artery* in 238 Patients 
p Value 
(chi-
square 
rt-PA VK test) 
Angiogram at 90 min n = 121 n = 117 
TIMI grade 2 or 3 84 (69.4%) 77 (65.8%) 0.56 
Angiogram at 24 h n = 105 n = 105 
TIM! grade 2 or 3 82 (78.1%) 77 (73.3%) 0.43 
Angiogram after> 10 days n = 86 n = 83 
TIMI grade 2 or 3 63 (73.3%) 59 (71.1%) 0.75 
* Angiograms at 24 h and after> 10 days were performed after various 
interventions (see Table 4). TIMI = Thrombolysis in Myocardial Infarction 
trial. Other abbreviations as in Table I. 
thrombolysis and the end of the first angiographic study. In 
the rt-PA group, one patient died in cardiogenic shock as a 
consequence of an extended anterior myocardial infarction 
and one patient had a cerebrovascular ischemic event with 
subsequent complete recovery. 
Cardiovascular complications including atrioventricular 
(A V) block and ventricular tachyarrhythmias were similar in 
both groups. A systolic blood pressure <90 mm Hg was seen 
more frequently in the urokinase group (13 versus 7 
patients). Both thrombolytic agents were well tolerated; no 
definite allergic reaction was reported with either drug. 
Angiographic findings. The patency of the infarct-related 
coronary artery as assessed from the angiograms by two 
independent observers unaware of other patient data is listed 
in Table 2 for both treatment groups. A 90 min angiogram 
(performed at a mean of 97 ± 10 min in either group) was 
evaluated in 98% of the rt-PA group and in 97% of the 
urokinase group, a 24 h angiogram in 85 and 87%, respec-
tively and a 2: 10 day angiogram in 69% of both groups. The 
patency rate of the infarct-related artery in both treatment 
groups did not differ significantly at 90 min, at 24 h or after 
10 days. 
Left ventricular angiograms suitable for interpretation 
were available in 89, 56 and 64% of patients at the first, 
second and third angiographic study, respectively. Left 
ventricular ejection fraction at the first, second and third 
angiographic study was 54 ± 15 versus 53 ± 14% (NS), 54 ± 
12 versus 52 ± 12% (NS) and 53 ± 12 versus 52 ± 14% (NS) 
for the rt-PA and the urokinase group, respectively. 
Interventions during first angiographic study (Table 3). 
Additional revascularization procedures in the patients with 
high grade residual stenosis or persisting occlusion of the 
infarct -related artery were left to the decision of the inves-
tigating physician. Thus, coronary angioplasty was at-
tempted in both treatment groups in a total of 52 patients (32 
rt-PA and 20 urokinase), intracoronary thrombolysis in 32, 
intravenous thrombolysis in 13 and emergency surgical 
bypass grafting in five patients. 
Reocclusion of the infarct-related artery (Table 4). In 102 
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Table 3. Interventions After Thrombolytic Therapy 
rt-PA UK 
Total Success Total Success 
A. Interventions During First Angiographic Study 
CABG 2 3 
PTCAonly 17 13 9 9 
PTCA and i.c. lysis 11 6 11 5 
PTCA and i. v. 4 0 
lysis 
i.c. lysis only 6 3 5 2 
i.v. lysis only 9 2 0 
B. Interventions After the First Angiographic Study 
CABG 7 12 
PTCA only 13 10 10 8 
PTCA and i.c. lysis 2 0 
PTCA and i.v. 0 
lysis 
i.c. lysis only 0 
i.v. lysis only 0 
CABG = coronary artery bypass grafting; i.c. = intracoronary; i.v. = 
intravenous; PTCA = percutaneous transluminal coronary angioplasty. Other 
abbreviations as in Table I. 
of the 124 patients treated with rt -P A the infarct -related 
artery was patent at completion of the first angiographic 
study, with or without additional recanalization procedures, 
compared with 87 of the 121 patients in the urokinase group. 
In 14 patients treated with rt-PA and 10 of the urokinase 
group, 24 h films were not obtained, leaving 88 and 77 
patients, respectively, with a patent artery who were re-
studied. A reocclusion rate of 14.8% was observed after 
rt-PA treatment as compared with a rate of 6.5% with 
urokinase treatment. In patients with a patent artery at the 
90 min angiographic study and no additional intervention, 
early reocclusion rate as assessed from the 24 h angiogram 
was 10.5% in the rt-PA group and 1.6% in the urokinase 
group (p = 0.08). Comparison oflate reocclusions as listed in 
Table 4 did not show a significant difference between the 
rt-PA and urokinase groups. 
Events during hospital stay. There were 11 deaths (4.5%) 
during the study period, 6 in the rt-PA and 5 in the urokinase 
group; all were due to cardiac causes with the exception of 
one fatal intracranial hemorrhage in the rt-PA group. Rein-
farction occurred in 27 patients, 11 (8.9%) in the rt-PA and 16 
(13.2%) in the urokinase group; this was not associated with 
a re-elevation of CK levels to > 100 U/liter in 11 of the 27 
patients. 
Apart from a slightly greater rate of bleeding at puncture 
sites in the urokinase group (22.3 versus 14.5%) and a 
slightly greater rate of angina pectoris after rt-PA treatment 
(35 versus 27%), bleeding and cardiovascular complications 
were evenly distributed in the two treatment groups. 
Table 4. Reocclusion Rate of Patent Infarct-Related Arteries in 
238 Patients 
p Value 
(chi-
rt-PA UK square 
(n=121) (n=l17) test) 
Patient artery 102 (84.3%) 87 (74.4%) 0.06 
(TIMI 2 or 3) after first 
angiographic study 
(including successful 
interventions) 
Reoccluded at 24 h 13/88 (14.8%) 5/77 (6.5%) 0.09 
(TIMI 0 or I) 
No angiographic study at 14 10 
24 h 
Reoccluded after> 10 days 7172 (9.8%) 8/62 (12.9%) 0.57 
(TIM I 0 or 1) 
No data 30 27 
Patient artery 63 66 0.51 
(TIMI 2 or 3) at 90 min 
angiogram without 
additional intervention 
Reoccluded at 24 h 6/57 (10.5%) 1163 (1.6%) 0.09' 
(TIMI 0 or I) 
No angiographic study 6 3 
at 24 h 
Reocc1uded after> 10 days 5/47 (10.6%) 5/49 (10.2%) 0.94 
(TIMI 0 or I) 
No data 18 18 
'Chi-square test corrected according to Yates. Abbreviations as in Tables 
I and 2. 
Systemic fibrinolysis. Systemic fibrinolytic effects as re-
flected in fibrinogen levels after infusion were significantly 
more frequent and pronounced with urokinase treatment. 
The fibrinogen level (local assessment, Clauss method [8]) 
before the infusion was 3.2 ± 1 glliter in both groups; 90 min 
after the end of the infusion it decreased to 2.9 ± 0.9 glliter 
in the rt-PA group and to 0.9 ± 0.9 glliter in the urokinase 
group (p < 0.001). A decrease below 1 glliter was found 90 
min after the end of the infusion in 12.7 versus 70%, 
respectively, of the patients receiving rt-PA and urokinase, 
and it persisted for :::::24 h in 4.5 versus 27.7%, respectively 
(p < 0.001). 
Discussion 
Several large clinical trials (9-12) have clearly demon-
strated the efficacy of intracoronary and intravenous throm-
bolysis with streptokinase in reducing both infarct size (9,10) 
and hospital mortality (11,12) from acute myocardial infarc-
tion. Therefore, interest has focused on improvement of the 
risklbenefit ratio of thrombolysis. The development of fibrin-
specific fibrinolytic agents, especially rt-PA, is considered a 
major step forward in this direction. In contrast to strepto-
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Table 5. Patency Rate of Infarct-Related Arteries 90 min After Start of Infusion 
Treatment 3 to 6 h After Symptom 
Total Treatment :53 h Onset 
TIMI rt-PA UK rt-PA 
Grade (n=121) (n=lI7) (n=72) 
67 (55.4%) 63 (53.8%) 35 (48.6%) 
p=0.81 
2 17 (14%) 14 (12%) II (15.3%) 
p=O.64 
o or I 37 (30.6%) 40 (34.2%) 26 (36.1%) 
p=0.56 
Abbreviations as in Tables I and 2. 
kinase, rt-PA has no antigenic or pyrogenic properties and it 
induces much less systemic fibrinolysis; reperfusion rates 
after its administration have been found superior to those 
after administration of streptokinase when both drugs were 
given intravenously (1,2). 
Recent experience (4) has shown, however, that the risk 
of bleeding with prolonged high dose rt-PA treatment (150 
mg over 6 h) may approach that of intravenous streptoki-
nase, and the rate of early reocclusion may be comparable 
with that after streptokinase treatment. Because urokinase 
offers the same advantages as rt-PA apart from fibrin spec-
ificity and has been shown to be effective in recanalization of 
infarct-related arteries (5), we tested rt-PA versus urokinase 
comparing a 90 min intravenous infusion of both agents with 
respect to patency and reocclusion rate of infarct-related 
arteries. 
Urokinase versus rt-PA dosage. According to available 
data at the time of study design, a total dose of 70 mg 
predominantly single-chain rt-PA administered over 90 min 
starting with a loading dose of 10 mg was chosen. For 
reasons of comparability, urokinase was also given over 90 
min with an initial bolus and a total dose of 3 million units. 
The dosage was derived from previous experience of one of 
us (K.L.N., unpublished data) with the use of a loading dose 
of 1 million units of urokinase followed by another million 
units over 60 min. This regimen was well tolerated with only 
minor bleeding complications as was the single 2 million unit 
bolus of urokinase reported by Mathey et al. (5). Because 
dose-ranging studies for urokinase and streptokinase are not 
available to date, the dosage of 3 million units may appear 
arbitrary. 
Coronary patency rates. Because pretreatment angio-
grams were not obtained in this study, only patency of 
infarct-related arteries at the end of fibrinolytic therapy can 
be compared. A major imbalance in the incidence of total 
occlusions, however, is unlikely because of the large sample 
size and the balanced baseline characteristics at entry into 
the study. In contrast to our assumptions, the patency rate at 
the end of infusion was very similar (69.4 versus 65.8%, 
UK rt-PA UK 
(n=70) (n=49) (n=47) 
44 (62.9%) 32 (65%) 19 (40%) 
p=0.08 p=O.OI 
5 (7.1%) 6 (12.2%) 9 (19.1%) 
p=0.12 p=0.35 
21 (30%) II (22.4%) 19 (40.4%) 
p=0.45 p=0.05 
TIMI grade 2 or 3) after treatment withrt-PA and urokinase, 
and almost identical with regard to prompt distal filling 
(TIMI grade 3) (55.4 versus 53.8%). 
These results are close to the patency rates reported for 
double-chain rt-PA in a dosage of 0.75 mg/kg over 90 min 
(1,13) and in a dosage of 80 mg over 3 h (2). With single-chain 
rt-PA a patency rate of 69%, which is identical to our result, 
was achieved by a similar cumulative dose of up to 70 mg at 
90 min in a subset of 71 patients studied by Topol et al. (14). 
The incidence of patent infarct-related arteries was greater 
after treatment with urokinase in the dosage used in this 
study than after a single bolus injection of 2 million units of 
urokinase in an uncontrolled study by Mathey et al. (5). This 
difference occurred even though the time from onset of 
symptoms to infusion, considered to be important for suc-
cessful thrombolysis (9,10), was shorter in the patients 
studied by Mathey et al. This finding is in agreement with the 
concept of a direct dose-related fibrinolytic effect of uroki-
nase. 
When the data are stratified for early (~3 h) and late 
treatment (3 to 6 h from symptom onset), urokinase seems to 
be more effective than rt-PA in achieving complete reperfu-
sion (TIMI grade 3) in the early treatment group, whereas in 
the late treatment group the patency rate was lower after 
urokinase (Table 5). This retrospective analysis, however, 
does not prove a time-related difference in thrombolytic 
efficacy despite its statistical significance because this sub-
group analysis had not been anticipated in the study proto-
col. 
Early coronary reocclusion. The problem of early reoc-
clusion after successful thrombolysis in this study was 
addressed by angiographic restudy of the infarct-related 
artery 24 h after fibrinolytic therapy. A 24 h coronary 
angiogram was available in 105 patients in each group (86.8% 
of the rt-PA and 89.7% of the urokinase group). Because 
there were more successful additional recanalization proce-
dures in the rt-PA group (28 versus 17), the total number of 
reocclusions during the first 24 h may be biased. The 
difference in favor of urokinase treatment (6.6 versus 14.8%) 
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is further confounded by the fact that > 10% of the patients 
did not have a 24 h angiogram. In those patients who did 
have a patent artery and no additional intervention, the 
difference in an early reocclusion rate of 1.6 versus 10.5% 
with urokinase and rt-PA treatment, respectively, gives rise 
to the hypothesis that the prolonged systemic lytic state after 
urokinase treatment may prevent early rethrombosis. The 
rate of early reocclusion in the rt-PA group, however, might 
well be adversely affected by the lower total dose and the 
shorter duration of treatment in our study as compared with 
others (2,3,14). 
Late coronary reocclusion. The data of this study suggest 
that reocclusion after the first 24 h is less affected than early 
reocclusion by the type of fibrinolytic agent, being about 
10% in both treatment groups. These angiographic findings 
are somewhat inconsistent with the total number of reinfarc-
tions, which was slightly larger (13.2 versus 8.9%) in the 
urokinase group. This seeming discrepancy may occur in 
part because the fact on the one hand, very early reocclusion 
may not appear clinically as a reinfarction and, on the other 
hand, prevention of early reocclusion will increase the 
potential for later reinfarction. The validity of these expla-
nations, however, cannot be assessed from the data of this 
trial for the reasons mentioned previously. 
Side effects. As expected, for both fibrinolytic agents 
occurring as natural human proteins, no significant side 
effects were observed. Despite the stronger fibrinogenolytic 
activity of urokinase, bleeding complications in the rt -P A 
and urokinase groups were similar apart from bleeding at 
puncture sites (14.5 versus 22.3%, NS). 
Conclusions. From the data of this study, we conclude 
that the risk-benefit ratio in the treatment of acute myocar-
dial infarction is similar for rt-PA and urokinase at least in 
the dosages that were used in this trial. The differences in 
coronary patency rate with early and late treatment and in 
the rate of early reocclusion have to be confirmed by further 
studies before definite conclusions may be reached. 
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